Abstract
The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.See related article by Casak et al., p. 1836.
©2021 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Comment
MeSH terms
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / therapeutic use
-
Carcinoma, Hepatocellular* / drug therapy
-
Humans
-
Liver Neoplasms* / drug therapy
Substances
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
atezolizumab